Biblio Discovery — Demo Discovery Service

35 hasil untuk "Kevin Kalinsky"

Menampilkan 1–20 · 1,55 detik · RSS

  1. Artikel Jurnal

    Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?

    Caitlin Taylor; Jane Meisel; Kevin Kalinsky

    Therapeutic Advances in Medical Oncology, Vol. 14 · 2022 · Inggris · DOAJ Scopus

    The treatment of hormone receptor-positive, HER2-negative breast cancer has become increasingly individualized, thanks to the development of genomic testing. Gene expression assays provide clinicians and patients with both prognostic and predictive information regarding breast cancer recurrence…

  2. Artikel Jurnal

    Caution over haste: why novel endocrine therapy in early lines should wait in Estrogen receptor positive human epidermal growth factor receptor 2 negative breast cancer

    Lan Lei; Manali Bhave; Kevin Kalinsky dkk.

    Breast Cancer Research, Vol. 28 No. 1 · 2026 · Inggris · DOAJ Scopus

    Abstract The rapid development of novel endocrine therapies (ETs), such as selective estrogen receptor degraders (SERDs), proteolysis targeting chimeras (PROTACs), selective estrogen receptor covalent antagonists (SERCAs), and complete estrogen receptor antagonists (CERANs) has generated enthusiasm…

  3. Artikel Jurnal

    Administration of trastuzumab deruxtecan in metastatic breast cancer patients with severe hepatic impairment

    Laura Sun; Gaybrielle Moore; Annalise Labatut dkk.

    Current Problems in Cancer: Case Reports, Vol. 16 · 2024 · Inggris · DOAJ Scopus

    Background: Trastuzumab deruxtecan (T-DXd) shows efficacy in HER2-positive and HER2-low metastatic breast cancer (MBC), but its safety in patients with hepatic impairment is unclear. Methods: We report three cases of MBC patients with significant liver dysfunction treated with dose-reduced T-DXd…

  4. Artikel Jurnal

    356 The Effect of Regional Anesthesia on Breast Cancer Recurrence

    Reema Martini; Anna Woodbury; Kevin Kalinsky dkk.

    Journal of Clinical and Translational Science, Vol. 8 · 2024 · Inggris · DOAJ Scopus

    OBJECTIVES/GOALS: To determine the impact of regional anesthesia (RA) on rates of breast cancer recurrence, breast cancer specific mortality, post mastectomy pain syndrome, and chronic opioid use among patients who received regional anesthesia during primary breast cancer surgery. METHODS/STUDY…

  5. Artikel Jurnal

    Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer

    Jessica Armand; Sungsoo Kim; Kibum Kim dkk.

    eLife, Vol. 14 · 2025 · Inggris · DOAJ

    CDK4/6 inhibitors (CDK4/6i) with endocrine therapy are standard for hormone receptor-positive (HR+) metastatic breast cancer. However, most patients eventually develop resistance and discontinue treatment, and there is currently no consensus on effective second-line strategies. Using preclinical…

  6. Artikel Jurnal

    Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study

    Nikita Consul; Xiaotao Guo; Courtney Coker dkk.

    Clinical Medicine Insights: Oncology, Vol. 2016 No. 10 · 2016 · Inggris · DOAJ Scopus

    Cachexia, a wasting syndrome associated with advanced cancer and metastasis, is rarely documented in breast cancer patients. However, the incidence of cachexia in breast cancer is now thought to be largely underestimated. In our case report of a breast cancer patient with bone metastasis monitored…

    Juga tersedia di: DOAJ

  7. Artikel Jurnal Teks lengkap

    Identifying Predictors of Taxane-Induced Peripheral Neuropathy Using Mass Spectrometry-Based Proteomics Technology

    Emily I. Chen; Katherine D. Crew; Meghna Trivedi dkk.

    PLOS ONE, Vol. 10 No. 12 · 2015 · Inggris · PLOS Scopus

    Major advances in early detection and therapy have significantly increased the survival of breast cancer patients. Unfortunately, most cancer therapies are known to carry a substantial risk of adverse long-term treatment-related effects. Little is known about patient susceptibility to severe side…

    Juga tersedia di: DOAJ

  8. Artikel Jurnal

    Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches

    David W. Cescon; Kevin Kalinsky; Heather A. Parsons dkk.

    Frontiers in Oncology, Vol. 11 · 2022 · Inggris · DOAJ Scopus

    While the majority of breast cancers are diagnosed at a curable stage, approximately 20% of women will experience recurrence at a distant site during their lifetime. These metastatic recurrences are incurable with current therapeutic approaches. Over the past decade, the biologic mechanisms…

  9. Artikel Jurnal

    Tuning Immune‐Cold Tumor by Suppressing USP10/B7‐H4 Proteolytic Axis Reinvigorates Therapeutic Efficacy of ADCs

    Lidan Zeng; Yueming Zhu; Xin Cui dkk.

    Advanced Science, Vol. 11 No. 40 · 2024 · Inggris · DOAJ Scopus

    Abstract Tuning immune‐cold tumor hot has largely attracted attention to improve cancer treatment, including immunotherapy and antibody‐drug conjugates (ADCs). Utilizing multiomic analyses and experimental validation, this work identifies a pivotal role for the USP10/B7‐H4 proteolytic axis in…

  10. Artikel Jurnal

    Molecular differences between younger versus older ER-positive and HER2-negative breast cancers

    Tao Qing; Thomas Karn; Mariya Rozenblit dkk.

    npj Breast Cancer, Vol. 8 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0–26, and in node-negative disease with RS 16–25, respectively, but no benefit in older women with the same clinical features. We…

  11. Artikel Jurnal

    Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer

    Douglas K. Marks; Robyn D. Gartrell; Margueritta El Asmar dkk.

    Frontiers in Oncology, Vol. 10 · 2020 · Inggris · DOAJ Scopus

    Background: The PI3K/Akt/mTOR pathway in part impacts tumorigenesis through modulation of host immune activity. To assess the effects of Akt inhibition on the tumor micro-environment (TME), we analyzed tumor tissue from patients with operable hormone receptor positive, HER2 negative breast cancer…

  12. Artikel Jurnal

    Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

    Sara A. Hurvitz; Aditya Bardia; Kevin Punie dkk.

    npj Breast Cancer, Vol. 10 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract In this post hoc analysis of the ASCENT study, we compared outcomes with sacituzumab govitecan (SG) vs single-agent chemotherapy in clinically important subgroups of patients with metastatic triple-negative breast cancer (mTNBC). Patients with mTNBC refractory to/relapsing after ≥2 prior…

  13. Artikel Jurnal

    Spatial biomarkers of response to eribulin plus pembrolizumab in patients with metastatic triple negative breast cancer in the ENHANCE-1 trial

    Yee Hoon Foong; Qi Wang; Matthew Kearney dkk.

    npj Breast Cancer, Vol. 11 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract ENHANCE-1 was a phase Ib/II study which evaluated eribulin plus pembrolizumab as a treatment for metastatic triple negative breast cancer (mTNBC). All patients had measurable disease and up to 2 prior systemic treatments. We identified 142 patients with available samples and evaluated…

  14. Artikel Jurnal

    Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

    Sara M. Tolaney; Muralidhar Beeram; J. Thaddeus Beck dkk.

    Frontiers in Oncology, Vol. 11 · 2022 · Inggris · DOAJ Scopus

    BackgroundCyclin-dependent kinases (CDK) 4 and 6 regulate G1 to S cell cycle progression and are often altered in cancers. Abemaciclib is a selective inhibitor of CDK4 and CDK6 approved for administration on a continuous dosing schedule as monotherapy or as combination therapy with an aromatase…

  15. Artikel Jurnal

    Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010–2021

    Alexandra Thomas; Anthony Rhoads; Erica L. Mayer dkk.

    npj Breast Cancer, Vol. 11 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Tumor biologic risk has replaced anatomic disease burden for guiding chemotherapy use in HR-positive, early-stage breast cancer. Recent surgical trials support less frequent axillary lymph node dissection, potentially impacting incidence of N2-3 diagnoses. As the field considers applying…

  16. Artikel Jurnal

    Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

    Mirella L. Altoe; Kevin Kalinsky; Alessandro Marone dkk.

    Breast Cancer Research, Vol. 23 No. 1 · 2021 · Inggris · DOAJ Scopus

    Abstract Background The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast…

  17. Artikel Jurnal Teks lengkap

    Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

    Fabrice Andre; Nofisat Ismaila; Kimberly H. Allison dkk.

    Journal of Clinical Oncology · 2022 · Inggris · OpenAlex Scopus

    PURPOSE To update recommendations on appropriate use of breast cancer biomarker assay results to guide adjuvant endocrine and chemotherapy decisions in early-stage breast cancer. METHODS An updated literature search identified randomized clinical trials and prospective-retrospective studies…